Research measuring the impact of light therapy or photobiomodulation (as it is also called) on reducing Parkinson’s symptoms in a group of Adelaide-based patients was published in BMC Neurology, a leading UK science journal. Congratulations to SYMBYX Co-founders and Scientific Advisors, Dr Ann Liebert, and Dr Brian Bicknell for their stewardship in completing this trial and published research. We have had many enquiries from people with Parkinson’s, as well as interested Carers, Neurologists, and health professionals upon publication of this research journal on 2 July 2021. The trial participants used the infrared PDCare Laser by SYMBYX.
Did you know? This important research was actually a catalyst for the forming of SYMBYX in 2019. Our vision is to see widespread use of light therapy in the treatment of diverse conditions, including Parkinson’s, Fibromyalgia and other microbiome or gut mediated indications.
The BMC manuscript concluded
“Photobiomodulation (PBM) was shown to be a safe and potentially effective treatment for a range of clinical signs and symptoms of Parkinson's (PD). Improvements were maintained for as long as treatment continued, for up to one year in a neurodegenerative disease where decline is typically expected. Home treatment of PD by the person themselves or with the help of a carer might be an effective therapy option. The results of this study indicate that a large RCT (Randomised Control Trial) is warranted”.
Please access the full manuscript at:https://bmcneurol.biomedcentral.com/articles/10.1186/s12883-021-02248-y.